Explore our ACCC 2020 Impact Report, the Oncology Issues, Vol.36, N.5, and our video podcast, CANCER BUZZ TV.

Industry News Archive

FDA Expands Cetuximab in Combination Label for Metastatic Colorectal Cancer

On September 28, 2021, the U.S. Food and Drug Administration (FDA) granted approval of a new indication for cetuximab in combination with encorafenib for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.

Read Eli Lilly's announcement.

Posted 9/29/2021

1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
Email Us